布雷非德菌素 A作用机制 - Medchemexpress - MCE中国

1、Product Data SheetBrefeldin ACat. No.: HY-16592CAS No.: 20350-15-6分式: CHO分量: 280.36作靶点: Autophagy; CRISPR/Cas9; Mitophagy; HSV作通路: Autophagy; Cell Cycle/DNA Damage; Anti-infection储存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性数据体外实验 DMSO : 20.83 mg/mL (74.30 mM; Need ultras

2、onic)SolventMass1 mg 5 mg 10 mgConcentration制备储备液1 mM 3.5668 mL 17.8342 mL 35.6684 mL5 mM 0.7134 mL 3.5668 mL 7.1337 mL10 mM 0.3567 mL 1.7834 mL 3.5668 mL请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；旦配成溶液，请分装保存，避免反复冻融造成的产品失效。储备液的保存式和期限：-80C, 6 months; -20C, 1 month。-80C 储存时，请在 6 个内使，-20C 储存时，请在 1 个内使。体内实验请根据您的实验动物和给

3、药式选择适当的溶解案。以下溶解案都请先按照 In Vitro 式配制澄清的储备液，再依次添加助溶剂：为保证实验结果的可靠性，澄 的储备液可以根据储存条件，适当保存；体内实验的作液，建议您现现配，当天使； 以下溶剂前显的百分 指该溶剂在您配制终溶液中的体积占；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的式助溶1. 请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% salineSolubility: 2.08 mg/mL (7.42 mM); Clear solution此案可获得 2.08 mg/mL (7.42 mM，饱和度未知) 的澄

4、清溶液。以 1 mL 作液为例，取 100 L 20.8 mg/mL 的澄 DMSO 储备液加到 400 L PEG300 中，混合均匀；向上述体系中加50 L Tween-80，混合均匀；然后继续加 450 L 理盐定容 1 mL。2. 请依序添加每种溶剂： 10% DMSO 90% (20% SBE-CD in saline)Solubility: 2.08 mg/mL (7.42 mM); Clear solution此案可获得 2.08 mg/mL (7.42 mM，饱和度未知) 的澄清溶液。Page 1 of 2 www.MedChemE以 1 mL 作液为例，取 100 L 20.

5、8 mg/mL 的澄均匀。DMSO 储备液加到 900 L 20% 的 SBE-CD 理盐溶液中，混合3. 请依序添加每种溶剂： 10% DMSO 90% corn oilSolubility: 2.08 mg/mL (7.42 mM); Clear solution此案可获得 2.08 mg/mL (7.42 mM，饱和度未知) 的澄 溶液，此案不适于实验周 期在半个以上的实验。以 1 mL 作液为例，取 100 L 20.8 mg/mL 的澄 DMSO 储备液加到 900 L 油中，混合均匀。BIOLOGICAL ACTIVITY物活性 Brefeldin A (BFA) 种内酯抗素， 蛋

6、质运输的特定抑制剂。Brefeldin A 阻断分泌蛋和膜蛋从内质向尔 体的转运。Brefeldin A 也 种噬 (autophagy) 和 mitophagy 抑制剂。Brefeldin A 还 种 CRISPR/Cas9 激动 剂，可抑制 HSV-1病毒，并具有抗癌活性。IC & Target CRISPR/Cas9体外研究 Brefeldin A (BFA) treatment for 15 h or 40 h, causes dramatic swelling of the Endoplasmic Reticulum (ER) and shifts itslocalization t

7、o the periphery of normal rat kidney (NRK) cells. Prolonged Brefeldin A treatment results in markeddisruption of the MT and actin cytoskeleton1. ADP-ribosylation of BARS is mediated by formation of a conjugatebetween Brefeldin A and ADPR. BARS shows BAC binding when incubated with the medium from th

8、e BFA-treatedCD38+ HeLa cells3. Brefeldin A induces anchorage-independent cell death in MDA-MB-231 breast cancer cells,inhibits the formation of MDA-MB-231 colonies in 3D and 2D cultures and inhibits the migration and MMP 9 (MatrixMetallopeptidase 9) activity of MDA-MB-2312.PROTOCOLCell Assay 1 Cell

9、s are grown on glass coverslips, fixed in 3 % paraformaldehyde in PBS (10 min at room temperature) and thenwashed in PBS. Cells are permeabilized with 0.01 % Triton X-lOO in PBS at room temperature for 7 min. The coverslipsare washed (3 times in PBS/0.2 % Tween) incubated in PBS/O.4 % fish skin gela

10、tin/0.2 % Tween (5 min) and in PBS/2.5% goat serum/0.2 % Tween (5 min.). After blocking, the cells are incubated with primary antibodies for 45 min at37C, and then washed with PBS/0.2 % Tween (5 times, 5 min each). The secondary antibodies are added for 30 minat 37C and then cells are washed as abov

11、e. Coverslips are mounted on slides in 9: 1 glycerol/PBS with 0.1 % o-phenylenediamine.MCE has not independently confirmed the accuracy of these methods. They are for reference only.户使本产品发表的科研献 J Autoimmun. 2019 May;99:39-47. Cell Death Dis. 2018 Nov 16;9(12):1143. FASEB J. 2019 Apr;33(4):5520-5534.

12、 J Cell Mol Med. 2019 Apr;23(4):2399-2409. Int J Nanomedicine. 2018 Jan 22;13:479-492.See more customer validations on HYPERLINK www.MedChemE www.MedChemEPage 2 of 3 www.MedChemEREFERENCES1. Alvarez C, et al. Brefeldin A (BFA) disrupts the organization of the microtubule and the actin cytoskeletons.

13、 Eur J Cell Biol. 1999 Jan;78(1):1-14.2. Colanzi A, et al. Molecular mechanism and functional role of brefeldin A-mediated ADP-ribosylation of CtBP1/BARS. Proc Natl Acad Sci U S A. 2013 Jun11;110(24):9794-9.3. Tseng CN, et al. Brefeldin A reduces anchorage-independent survival, cancer stem cell pote

14、ntial and migration of MDA-MB-231 human breast cancercells. Molecules. 2014 Oct 29;19(11):17464-77.4. Wang J, et al. Erythroleukemia cells acquire an alternative mitophagy capability. Sci Rep. 2016 Apr 19;6:24641.5. Yu C, et al. Small molecules enhance CRISPR genome editing in pluripotent stem cells. Cell Stem Cell. 2015 Feb 5;16(2):142-7.6. Nozawa N, et al. Subcellular localization of herpes simplex virus type 1 UL51 protein and role of palmitoylation in Golgi apparatus targeting. J Virol. 2003Mar;77(5):3204-16.M